354 results about "Membrane protein" patented technology

The invention discloses a method for promoting dissolution of eggshell membrane protein and preparing chelated calcium through high-pressure crushing. Comprising the following steps: separating and drying eggshells and eggshell membranes of egg shells, and respectively carrying out superfine grinding to obtain eggshell powder and eggshell membrane powder; adding water into the eggshell membrane powder, carrying out high-pressure homogenization, and centrifuging to obtain an eggshell membrane solution; adding eggshell powder into the eggshell membrane solution, adjusting the pH value to 1-3, and adding pepsase for reaction; after the reaction, adjusting the pH value of the eggshell membrane solution to 6.5-7.5, and adding trypsin for reaction; and after the reaction, inactivating the enzyme, centrifuging to take a supernatant, adding absolute ethyl alcohol into the supernatant for alcohol precipitation, and centrifuging to obtain a precipitate, namely the chelated calcium. The technical problem that the eggshell membrane protein is difficult to dissolve out is solved, and a new way is provided for industrial extraction of the eggshell membrane soluble protein.

Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.

The present invention relates to the field of lentiviral delivery. Specifically provided are a mutated vesicular virus envelope protein and the use thereof in lentiviral vector packaging.

The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.

The invention discloses an all-optical three-dimensional scanning confocal fluorescent microscopic imaging device and an implementation method thereof. According to the invention, through a deep learning driven adaptive regulation and control method, CNN is adopted to process spatial distribution data and dynamically regulate and control a phase hologram and the light intensity and phase compensation of a laser, so that the focal point of exciting light is subjected to aberration-free axial displacement, a bidirectional parallel optical scanning track of a two-dimensional scanning system is optimized, and all-optical three-dimensional scanning is realized; lSTM and TCN are combined to obtain a time sequence dependency relationship, a laser light source, an adjustable diaphragm, an electric focus-adjustable lens and a photoelectric detector are integrally controlled, efficient synchronization and automatic operation and high-speed axial focusing adjustment are realized, errors and time sequence mismatch are eliminated, optical characteristics of different samples and environmental interference are automatically adapted, and high-quality imaging is kept. The robustness and the applicable scene range of the system are improved; the method is used for model biological embryo real-time tracking, intracellular signal molecule dynamic visualization, cell membrane protein migration and aggregation observation and intracellular organelle interaction tracking.

The invention relates to a recombinant bacterium for overexpressing uranyl binding protein and application of the recombinant bacterium, and belongs to the technical field of microorganisms. Bacterial outer membrane protein and uranyl binding protein are expressed in host bacteria, and the uranyl binding protein is anchored on an outer membrane of recombinant bacteria through the bacterial outer membrane protein, so that the uranyl binding protein anchored on the bacterial outer membrane can adsorb uranyl ions. Meanwhile, the invention finds that the expression quantity of the uranyl binding protein can be increased by performing fusion expression on the uranyl binding protein by using LPP-OMPA, so that the adsorption effect of uranyl ions is improved. The recombinant bacterium is prepared into a freeze-dried capsule product, and the freeze-dried capsule product can penetrate through a stomach barrier and is accurately delivered to intestinal tracts so as to realize uranyl ion adsorption.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

The invention relates to the technical field of biological genetic engineering, in particular to construction of recombinant lactobacillus plantarum of an African swine fever virus antigen, and the method comprises the following steps: constructing a lactobacillus plantarum shuttle vector containing different ASFV antigen genes; and referring to a genome sequence of a Chinese isolate CADCHN09 of ASFV disclosed in GenBank. The method has the advantages that an inducer is not needed, antigen protein is efficiently expressed, the dendritic cell (DC) binding peptide for enhancing immune cell uptake and processing is subjected to fusion expression, the oral immunization mode is simple, mucosal immunity is stimulated, and ASFV infection is effectively prevented and controlled; probiotics, namely lactobacillus plantarum, which naturally exist in animal intestinal tracts and can be colonized and copied in digestive tracts for a long time are used as a carrier; key epitopes of proteins such as nucleocapsid protein p72, outer envelope protein CD2v, inner envelope protein p54, p22, pE199L and pE248R, which play an important role in adsorption, internalization, endocytosis and membrane fusion of ASFV, are preferably fused with dendritic cell binding peptide and then are displayed on the surface of lactobacillus plantarum.

The invention discloses a dental sac mesenchymal stem cell with high periostin expression as well as an extraction and culture method and application thereof, and belongs to the technical field of biomedicine. The dental sac mesenchymal stem cell with high periostin expression is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C2024384; the extraction and culture method disclosed by the invention comprises the following steps: S1, extraction: cleaning, cutting, digesting and centrifuging dental sac tissues, resuspending, centrifuging and precipitating by using a primary culture medium, culturing until cells are fused, digesting, and carrying out secondary centrifugation and precipitating to obtain primary dental sac mesenchymal stem cells; s2, subculture: resuspending the dental sac mesenchymal stem cells in the step S1 by using a primary culture medium, supplementing a subculture medium, and then subculturing. The invention also discloses the dental sac mesenchymal stem cell with high periostin expression and application of the dental sac mesenchymal stem cell in preparation of medicines for preventing or / and treating periodontal diseases. The method disclosed by the invention has an unexpected effect of enhancing periostin expression of the dental sac mesenchymal stem cells.

The invention belongs to the technical field of antibodies, and discloses an antibody for resisting novel coronavirus envelope protein or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; a heavy chain of the antibody or the antigen binding fragment thereof comprises: a heavy chain variable region, wherein the heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3; a light chain of the antibody or the antigen binding fragment thereof comprises a light chain variable region, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody or the antigen binding fragment thereof can be used for detecting the existence or the level of the novel coronavirus envelope protein in a sample, detecting the novel coronavirus and diagnosing diseases related to novel coronavirus infection.

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.

The invention belongs to the technical field of collagen skin care products, and provides an oil-soluble recombinant collagen bionic nano-liposome delivery system and a preparation method and application thereof.The preparation method comprises the steps that A, a buffer solution with the pH being 3.8-4.2 is added into a lipid film, oscillation and ultrasonic treatment are conducted, and blank liposome is obtained; b, dissolving the integrin alpha6beta4 transmembrane protein by using a buffer solution with the pH value of 7.2-7.4; adding the transmembrane protein solution into blank lipidosome, oscillating and incubating at 37 DEG C, and performing ultrafiltration and centrifugation to obtain lipidosome suspension; c, dropwise adding the recombinant collagen solution into the liposome suspension, stirring at a constant temperature of 40 + / -2 DEG C, and performing ultrasonic treatment to obtain a collagen liposome suspension; and D, homogenizing the collagen liposome suspension at high pressure, and performing ultrafiltration purification to obtain the purified collagen liposome suspension. Through the technical scheme, the problems of low collagen encapsulation efficiency and low transdermal efficiency in the prior art are solved.

The invention relates to the technical field of organelle separation, and provides a combination of ATF6 alpha N protein and peroxisome, application of the ATF6 alpha N protein in separation and purification of the peroxisome and a method for separating and purifying the peroxisome. The ATF6 alpha N protein is combined with membrane protein PMP70 and / or ABCD1 of the peroxisome; the method comprises the following steps: combining tagne-ATF6 alpha N fusion protein with a medium to obtain a fusion protein-medium compound; adding a roughly separated peroxisome sample into the fusion protein-medium compound, so as to obtain a fusion protein-medium-peroxisome compound; and adding an elution buffer solution, and collecting the eluent to obtain the peroxisome combined with the fusion protein. The method is easy and convenient to operate, complex instruments and equipment are not needed, the peroxisome can be separated from cells and tissues, and the obtained peroxisome is high in purity and can be used for conventional experiments such as subsequent protein spectrum analysis and flow analysis.

Provided herein are transmembrane proteins containing a cytokine or a functional portion thereof, such as an interleukin or a functional portion thereof. In some aspects, the disclosure further relates to engineered cells and compositions comprising the transmembrane proteins and methods for their administration to subjects. In some embodiments, the cells engineered to contain the transmembrane protein, such as immune cells, further contain a genetically engineered recombinant receptor, such as a chimeric antigen receptor (CAR). In some embodiments, features of the transmembrane proteins, engineered cells, and methods and uses thereof provide for improved treatment of diseases or disorders.

The present invention belongs to the technical field of microbial synthesis of astaxanthin, and discloses an astaxanthin-producing Yarrowia lipolytica engineered strain, a construction method and application thereof, and a method for preparing astaxanthin. The Yarrowia lipolytica engineered strain provided by the present invention overexpresses peroxisomal membrane protein PEX11 and peroxisomal targeting signal type I receptor PEX5, and can simultaneously synthesize and express β-carotene hydroxylase and β-carotene ketolase. The Yarrowia lipolytica engineered strain has excellent astaxanthin synthesis ability and astaxanthin cell volume, can achieve high-yield synthesis of astaxanthin, provides a basis for large-scale industrial production of astaxanthin, and has good application prospects.

The invention discloses a preparation method of a monomeric protein and hydrophobic transmembrane protein complex, which comprises the following steps: 1) preparing a protein A containing the monomeric protein, the C end of the monomeric protein in the protein A having a connection sequence for connecting with the hydrophobic transmembrane protein; the connecting sequence comprises at least two amino acids; preparing a protein B containing a hydrophobic transmembrane protein monomer; and 2) connecting the protein A with the protein B, and polymerizing the hydrophobic transmembrane protein monomers in the plurality of protein B to form the hydrophobic transmembrane protein, thereby obtaining the monomeric protein and hydrophobic transmembrane protein complex.

A composition is orally or topically administered to a patient susceptible to infection by an orthopoxvirus such as monkeypox (mpox). The composition includes inhibitors configured to bind to orthopoxvirus envelope proteins, e.g., MPXV A29 from mpox. The inhibitors can include sulfated polysaccharides or glycans such as heparin, chondroitin sulfate A, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate C, chondroitin sulfate D, chondroitin sulfate E, pentosan polysulfate, mucopolysaccharide polysulfate, or combinations thereof. Binding of the composition to the envelope proteins inhibits the interaction between the virions and heparan sulfate proteoglycans (HSPG) and thus the ability of the virions to enter the host cell. Limiting this transport across the host cell membrane inhibits initial viral infection, as well as limits spread of that infection from cell to cell even in the event viral infection is initially achieved, providing significantly improved patient treatment and recovery outcomes relating to orthopoxvirus infections such as mpox.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

Disclosed are a recombinant interferon drug targeting a conserved HIV gp41 subunit membrane-proximal external region (MPER) and a use thereof. Specifically, disclosed is a targeted interferon fusion protein ZP-IC, comprising a 10E8 antibody or an antigen-binding fragment thereof, and an integrated interferon α, wherein the 10E8 antibody or the antigen-binding fragment thereof is linked to the integrated interferon α by means of a linker. In the present invention, the 10E8 antibody capable of identifying a highly conserved gp41 subunit MPER of an HIV envelope glycoprotein is used as a targeting tool for the integrated interferon. Therefore, a target exposed by a conformational change of a viral envelope protein during the infection of a cell can be accurately identified, viral infection is prevented, and a neutralizing effect is exerted; and in addition, a carried interferon molecule can more effectively bind to an interferon receptor on a cell around the HIV virus and achieve an antiviral role. Experiments have demonstrated that the ZP-IC has excellent antiviral activity and the capability of inhibiting an overwhelming majority of HIV strains across a broad spectrum.

The invention relates to a transmembrane protein and transmembrane protein interaction prediction method, computer equipment and a storage medium, and the method comprises the steps: inputting an amino acid sequence 1 of protein 1 and an amino acid sequence 2 of protein 2 into a transmembrane prediction neural network, and when an output result identifies that the two proteins are transmembrane proteins, determining the transmembrane protein interaction between the two proteins; screening an extracellular amino acid fragment sequence 1 of the protein 1 and an extracellular amino acid fragment sequence 2 of the protein 2 from output results of the transmembrane prediction neural network; the extracellular amino acid fragment sequence 1 and the extracellular amino acid fragment sequence 2 are input into a trained attention mechanism model, an interaction score is obtained, and the interaction score is used for representing the interaction possibility of the protein 1 and the protein 2. According to the method, the interaction between the transmembrane protein and the transmembrane protein is automatically determined in a computer mode, and excessive manpower and material resources do not need to be consumed.

Fusion proteins containing a targeting sequence, an exosporium protein, or an exosporium protein fragment that targets the fusion protein to the exosporium of a Bacillus cereus family member are provided. Recombinant Bacillus cereus family members expressing such fusion proteins are also provided. Genetically inactivated Bacillus cereus family members and recombinant Bacillus cereus family members that overexpress exosporium proteins are also provided. Seeds coated with the recombinant Bacillus cereus family members and methods for using the recombinant Bacillus cereus family members (e.g., for stimulating plant growth) are also provided. Various modifiations of the recombinant Bacillus cereus family members that express the fusion proteins are further provided. Fusion proteins comprising a spore coat protein and a protein or peptide of interest, recombinant bacteria that express such fusion proteins, seeds coated with such recombinant bacteria, and methods for using such recombinant bacteria (e.g., for stimulating plant growth) are also provided.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

This disclosure relates to a recombinant adenovirus comprising a polynucleotide encoding DENV envelope protein and a polynucleotide encoding ferritin heavy chain protein, and uses thereof. This disclosure also provides a recombinant adenovirus comprising a polynucleotide encoding DENV (Dengue Virus) envelope protein and a polynucleotide encoding ferritin heavy chain protein, and a vaccine composition for preventing DENV infection comprising the recombinant adenovirus as an effective ingredient.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None

The application relates to a hybridoma cell strain 1B6A2 secreting an anti-fish T lymphocyte surface membrane protein CD28 monoclonal antibody, the hybridoma cell strain 1B6A2 is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202291, and the preservation date is May 5, 2022. The application provides a powerful tool for simulating a second signal in vitro and exploring a CD28-mediated T cell adaptive immune response mechanism.

To provide methods for treating viral infections including SARS-CoV-2, and to provide polymers for use in such treatments.SOLUTION: Provided are improved amphiphilic comb-type polymers with well-controlled molecular weights, structures, and end groups, and hydrophilic backbones with regularly arranged hydrophobic substituents. The polymers self-assemble in an aqueous environment to form core-corona nanoparticles that are capable of disrupting envelope proteins of a virus and can further encapsulate antiviral drugs or their prodrugs. Regularly arranged targeting groups can also mediate the attachment of the nanoparticles to an envelope of the virus.SELECTED DRAWING: Figure 2